Home > Insider Trading > Filing (0001209191-11-054508)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1333248	Cadence Pharmaceuticals Inc	CADX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1244823	B James Breitmeyer	C/O Cadence Pharmaceuticals, Inc. 12481 High Bluff Drive, Suite 200 San Diego CA 92130	Evp, Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-11-02	12,500	$0.00	22,500	No	4	M	Direct
Common Stock	Disposition	2011-11-03	12,500	$5.70	10,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2011-11-02	12,500	$0.00	12,500	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Each restricted stock unit represented the right to receive one share of common stock on the earlier of (a) the one-year anniversary of FDA approval of the Company's NDA for intravenous acetaminophen, and (b) immediately prior to the consummation of a change in control of the Company, subject to the recipient's continued status as an employee, independent director or consultant of the Company or any subsidiary on the applicable vesting date. The Company received FDA approval of its NDA for intravenous acetaminophen on November 2, 2010.
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2011.
This transaction was executed in multiple trades at prices ranging from a low of $5.65 to a high of $5.76. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.